Enveloped virus membrane protein

Enveloped virus membrane proteins are a diverse class of proteins embedded in the lipid bilayer of enveloped viruses, such as HIV-1, Influenza, and SARS-CoV-2 (Source: NCBI Bookshelf, 2021). These proteins are essential for the viral life cycle, primarily mediating the attachment of the virus to specific host cell receptors and facilitating the fusion of the viral and cellular membranes to allow genome entry (Source: UniProt, 2023). They are often heavily glycosylated to shield the virus from the host immune system, yet they remain the primary targets for neutralizing antibodies and vaccine development. In clinical practice, these proteins are targeted by various antiviral agents, including fusion inhibitors like enfuvirtide and ion channel blockers like amantadine (Source: PubChem, 2024). However, the high mutation rate of these proteins, particularly in RNA viruses, presents a significant challenge for long-term therapeutic efficacy and often leads to the rapid emergence of drug-resistant variants (Source: PubMed, 2022).

Other names

Viral envelope proteinViral surface glycoproteinViral membrane proteinEnvelope glycoprotein

Drugs targeting these proteins primarily act by inhibiting viral entry through the blockade of attachment to host receptors or the prevention of conformational changes required for membrane fusion. Some agents function as ion channel blockers to prevent viral uncoating, while others are neutralizing antibodies that bind to surface epitopes to prevent infection (Source: Nature Reviews Microbiology, 2018).